Value Assessment of Ophthalmic Pharmaceutical Enterprises Based on Real Option Model
With the acceleration of the aging process and the popularity of electronic devices,the market demand for ophthalmic drugs continues to expand,and corporate activities in the industry are frequent such as investment,mergers and acquisitions.Ophthalmic pharmaceutical companies are at the peak of drug research and development,with huge capital investment,so the traditional method of valuation is likely to underestimate the true value of enterprises.This paper deeply analyzes the development status and enterprise characteristics of the ophthalmic pharmaceutical industry,and divides the enterprise value into existing value and potential value for separate evaluation.EVA model is used to calculate the existing value of the enterprise,and the paper uses grey prediction model to improve future EVA prediction part of the enterprise.The real option model is used to calculate the potential value of the enterprise.Finally,through related cases,the high applicability of the combined model for the valuation of ophthalmic pharmaceutical companies is proved.
real option methodEVA modelgrey prediction modelophthalmic pharmaceutical enterprises
万方数据
维普
